Brook­ings pan­el of ex­perts lays out case for on­shoring man­u­fac­tur­ing

As the US and Eu­rope con­tin­ue to con­sid­er on­shoring phar­ma man­u­fac­tur­ing to shore up the in­ter­na­tion­al sup­ply chain, a pan­el of ex­perts, host­ed by the Brook­ings In­sti­tu­tion, ad­dressed how to shore up sup­plies and re­silien­cy as drug short­ages and oth­er sup­ply is­sues per­sist af­ter the pan­dem­ic’s ini­tial im­pact.

Speak­ing on lessons learned from the pan­dem­ic, Tom Bol­lyky, di­rec­tor of the Glob­al Health Pro­gram and Se­nior Fel­low for Glob­al Health, Eco­nom­ics and De­vel­op­ment at the Coun­cil on For­eign Re­la­tion, said that while there was gen­er­al suc­cess in mov­ing bil­lions of dos­es of the Covid-19 vac­cine once it be­came more wide­ly avail­able, there were still some dif­fi­cul­ties. More than two-thirds of coun­tries had ex­port re­stric­tions on es­sen­tial med­ical prod­ucts dur­ing the pan­dem­ic, Bol­lyky said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER